Phase 2 trials typically test preliminary efficacy and further safety in a larger patient group, and are a frequent point of failure for new drugs. Understanding this stage is essential when interpreting AI‑reported probabilities of moving from phase 2 to phase 3, because decisions here can redirect major investments and directly affect whether promising therapies progress or stop.